Walvax沃森生物

CN
EN

Products List

Walvax has successfully developed 8 licensed vaccines, including 13-valent Pneumococcal Polysaccharide Conjugate Vaccine (PCV13) and Recombinant Human Papillomavirus Bivalent (Types 16,18) Vaccine (HPV2).

 

Walvax proactively promotes PQ application of its products, and is proceeding with PQ application of multiple products. In 3 to 5 years, Walvax's WHO-PQ will yield fruitful results, which brings its internationalization to a higher level.

Quick Links

Pipeline
All Products Pneumococcal Vaccine Series Meningococcal Vaccine Series Other Vaccines
Recombinant Human Papillomavirus Bivalent (Types 16, 18) Vaccine (Pichia pastoris)
Package Insert

For the prevention of cervical cancers and precancerous lesions caused by human papillomavirus types 16/18.

13-valent Pneumococcal Polysaccharide Conjugate Vaccine
Package Insert

Prevention of invasive diseases caused by 13 serotypes of Streptococcus pneumoniae for use in infants and children 6 weeks through 5 years of age (below 6 years).

23-valent Pneumococcal Polysaccharide Vaccine
Package Insert

Prevention of invasive diseases caused by 23 serotypes of Streptococcus pneumoniae for use in individuals aged ≥ 2 years who are at increased risk of pneumococcal diseases.

Group ACYW135 Meningococcal Polysaccharide Vaccine
Package Insert

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A, C, Y and W135 for use in individuals aged ≥ 2 years.

Group A and C Meningococcal Polysaccharide Vaccine
Package Insert

Prevention of epidemic cerebrospinal meningitis caused by Neisseria meningitidis serogroups A and C for use in individuals aged ≥ 2 years.

Group A and Group C Meningococcal Conjugate Vaccine
Package Insert

Prevention of invasive meningococcal diseases caused by Neisseria meningitidis serogroups A and C for use in infants and children 3 months through 5 years of age.

Haemophilus Influenzae Type b Conjugate Vaccine
Package Insert

Prevention of invasive infections caused by Haemophilus Influenzae type b for infants and children 2 months through 5 years of age.

Diphtheria, Tetanus and Acellular Pertussis Combined Vaccine, adsorbed

Prevention of pertussis, diphtheria and tetanus for infants and children 3 months through 6 years of age.